Exploration of Safety, Pharmacokinetics and Selected Pharmacodynamic Mechanisms of High-Dose Se-Methylselenocysteine, L-Selenomethionine and Selenite in a Phase Ib Trial in Cancer Patients.

Catherine M Turnbull, Stephen O Evans, Linda M Peters, Renee J Goodall, Craig K Burns, Hugh J B Goodman, Natalie Briggs, Michael B Jameson

Abstract readClinical Trial, Phase IRandomized Controlled Trial

PubMed Full text at PMC Publisher

In one paragraph

Trial report in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Catherine M TurnbullFaculty of Medical and Health Sciences, Waikato Clinical Campus, University of Auckland, Hamilton 3204, New Zealand.

Stephen O EvansSchool of Pharmacy and Biomedical Sciences, University of Waikato, Hamilton 3240, New Zealand.ORCID 0000-0002-3426-0973

Linda M PetersSchool of Science, University of Waikato, Hamilton 3240, New Zealand.ORCID 0000-0002-9961-4293

Renee J GoodallSchool of Science, University of Waikato, Hamilton 3240, New Zealand.

Craig K BurnsSchool of Science, University of Waikato, Hamilton 3240, New Zealand.

Hugh J B GoodmanHaematology Department, Waikato Hospital, Hamilton 3204, New Zealand.

Natalie BriggsOncology Department, Waikato Hospital, Hamilton 3204, New Zealand.

Michael B JamesonFaculty of Medical and Health Sciences, Waikato Clinical Campus, University of Auckland, Hamilton 3204, New Zealand.ORCID 0000-0001-7068-4311

Funding

Cycle for Life N/AGenesis Oncology Trust N/AWaikato Medical Research Foundation 310

6 · The paper itself

Abstract

High-dose selenium (Se) as selenomethionine (SLM) and sodium selenite (SS) can improve the efficacy of cancer therapies while reducing toxicity. Se-methylselenocysteine (MSC) is effective in preclinical models but has not been evaluated in cancer trials. This phase Ib randomised, double-blinded trial explored the safety, pharmacokinetics (PK) and selected pharmacodynamic (PD) mechanisms of MSC, SLM and SS to guide future trials. Nine participants with metastatic cancer took Se 1600 μg/day for 4 weeks, then 6400 μg/day for 4 weeks, as MSC, SLM, or SS, with safety, PK, and PD assessments at baseline then every 4 weeks for 12 weeks. No dose-limiting toxicities occurred, and all adverse events were grades 1-2, mainly gastrointestinal. Total plasma Se increased after 8 weeks to mean 27.2 μM with SLM, 4.14 μM with MSC and 3.90 μM with SS. No significant changes in DNA damage or intracellular glutathione were observed in peripheral blood mononuclear cells. Mean plasma selenoprotein P (SEPP) increased from 3.74 mg/L at baseline to 4.66 mg/L and 5.13 mg/L after 4 and 8 weeks (

Indexed as

NeoplasmsSelenious AcidSelenocysteineSelenomethionineAdultAgedDouble-Blind MethodFemaleGlutathioneHumansMaleMiddle AgedGlutathioneSelenious AcidSelenocysteineSelenomethionineselenomethylselenocysteinecancerclinical trialgenotoxicityglutathionemethylselenocysteinepharmacokineticsseleniteseleniumselenomethionineselenoprotein P

Identifiers

PMID42589275

DOI10.3390/ijms27156618

PMCPMC13465172

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.